Suvorexant
Brand name: Belsomra
Rank #290 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$40.7M
Total Cost
87,327
Total Claims
$40.7M
Total Cost
4,036
Prescribers
$466
Cost per Claim
5,509
Beneficiaries
94,124
30-Day Fills
$10K
Avg Cost/Provider
22
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$40.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $40.7M total
🔎 Data Overview
Average cost of $7,384 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Suvorexant
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | James Rini | Neurology | Mobile, AL | 416 | $196K |
| 2 | Jyh-Haur Lu | Neurology | Flushing, NY | 383 | $175K |
| 3 | Ernesto Zilberberg | Psychiatry | North Andover, MA | 298 | $140K |
| 4 | Robert Morton | Psychiatry | Ada, OK | 317 | $136K |
| 5 | Kenia Castro | Psychiatry | Hialeah, FL | 299 | $134K |
| 6 | Stephen Kelly | Family Practice | Oklahoma City, OK | 228 | $110K |
| 7 | William Bara-Jimenez | Neurology | Kensington, MD | 184 | $93K |
| 8 | Marina Kovalevsky | Internal Medicine | Los Angeles, CA | 202 | $91K |
| 9 | Ferdinant Saran | Geriatric Medicine | Glendale, CA | 163 | $78K |
| 10 | John Damergis | Sleep Medicine | Bloomington, MN | 103 | $76K |
| 11 | Lorna Barte | Psychiatry | Camarillo, CA | 106 | $70K |
| 12 | Carlos Perez | Psychiatry | Dalton, GA | 136 | $69K |
| 13 | Megan Chavez | Physician Assistant | Mcallen, TX | 148 | $67K |
| 14 | Ramon Sanchez | Psychiatry | San Antonio, TX | 145 | $65K |
| 15 | Zaven Arslanian | General Practice | Glendale, CA | 112 | $64K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 287 | Daptomycin (Daptomycin) | $41.2M | 41,245 |
| 288 | Pitavastatin Calcium (Livalo) | $40.8M | 69,636 |
| 289 | Bromfenac Sodium (Prolensa) | $40.8M | 121,284 |
| 290 | Suvorexant (Belsomra) | $40.7M | 87,327 |
| 291 | Atogepant (Qulipta) | $40.7M | 32,955 |
| 292 | Obeticholic Acid (Ocaliva) | $40.6M | 4,131 |
| 293 | Doxycycline Hyclate (Doxycycline Hyclate) | $40.5M | 2,023,357 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology